Patients responded better to treatment with POTELIGEO in real life, compared to data from the pivotal Phase 3 MAVORIC trial1 Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary
Patients treated with POTELIGEO? (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients afp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afp.com Daily Mail and Mail on Sunday newspapers.
Patients treated with POTELIGEO®▼ (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the European Hematology Association meeting1GALASHIELS, Scotland (BUSINESS WIRE) Kyowa Kirin International PLC (Kyowa Ki.